Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Straley

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Blood|November 16, 2014
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibitionAndrew Kernytsky, Fang Wang, Erica Hansen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2011
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Fredrick Van Goor, Sabine Hadida, Peter D J Grootenhuis, et al.
The Oncologist|April 25, 2014
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarateAmir T Fathi, Hossein Sadrzadeh, Amy H Comander, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2016
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered miceZhenyue Hao, Rob A Cairns, Satoshi Inoue, et al.
Clinical Cardiology|May 11, 2012
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 TrialDavid E Kandzari, Deepak L Bhatt, Paul A Sobotka, et al.
Nature Genetics|November 8, 2011
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2M Fernanda Amary, Stephen Damato, Dina Halai, et al.
Cancer Discovery|February 15, 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid LeukemiaAlan H Shih, Cem Meydan, Kaitlyn Shank, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 31, 2006
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small moleculesFredrick Van Goor, Kimberly S Straley, Dong Cao, et al.
The Journal of Infectious Diseases|July 14, 2026
Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem HelixFrancesco Borriello, Gavin C K W Koh, Iñaki F Troconiz, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoJaneta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Blood|November 16, 2014
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibitionAndrew Kernytsky, Fang Wang, Erica Hansen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2011
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Fredrick Van Goor, Sabine Hadida, Peter D J Grootenhuis, et al.
The Oncologist|April 25, 2014
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarateAmir T Fathi, Hossein Sadrzadeh, Amy H Comander, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2016
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered miceZhenyue Hao, Rob A Cairns, Satoshi Inoue, et al.
Clinical Cardiology|May 11, 2012
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 TrialDavid E Kandzari, Deepak L Bhatt, Paul A Sobotka, et al.
Nature Genetics|November 8, 2011
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2M Fernanda Amary, Stephen Damato, Dina Halai, et al.
Cancer Discovery|February 15, 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid LeukemiaAlan H Shih, Cem Meydan, Kaitlyn Shank, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 31, 2006
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small moleculesFredrick Van Goor, Kimberly S Straley, Dong Cao, et al.
The Journal of Infectious Diseases|July 14, 2026
Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem HelixFrancesco Borriello, Gavin C K W Koh, Iñaki F Troconiz, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoJaneta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, et al.
Pageof 19